Marché des intermédiaires pharmaceutiques – Analyse des tendances et de la croissance | Année de prévision 2031

  • Report Code : TIPRE00005559
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 185
Buy Now

Le marché des intermédiaires pharmaceutiques devrait atteindre 37 290,33 millions de dollars américains en 2028 contre 27 356,70 millions de dollars américains en 2020. Le marché devrait croître avec un TCAC de 4,2 % de 2021 à 2028.



Le Le marché des intermédiaires pharmaceutiques a été analysé en fonction du type, de l'application, du canal de distribution et de la région. Le marché basé sur la région est segmenté en Amérique du Nord, en Europe, en Asie-Pacifique, au Moyen-Orient et en Afrique, et en Amérique du Sud et centrale. Le rapport met l'accent sur des paramètres tels que les tendances du marché, les avancées technologiques, la dynamique du marché et l'analyse du paysage concurrentiel de l'entreprise leader pour offrir des informations et une analyse approfondie du marché des intermédiaires pharmaceutiques. Il comprend également l'analyse de la pandémie de COVID-19 sur le marché dans toutes les régions clés.



Régions lucratives pour le marché des intermédiaires pharmaceutiques



Aperçu du marché



Prévalence croissante des maladies chroniques et des maladies infectieuses



< p>Les intermédiaires pharmaceutiques sont les éléments constitutifs des ingrédients pharmaceutiques actifs (API). Ce sont des matières premières qui subissent un changement moléculaire ou un traitement lors de la production de médicaments en vrac. Ainsi, les besoins en intermédiaires pharmaceutiques augmentent avec l'augmentation de la demande de médicaments pour traiter les maladies chroniques. Selon les Centers for Disease Control and Prevention (CDC), 6 adultes sur 10 aux États-Unis souffrent d'au moins une maladie chronique comme le cancer, les maladies cardiaques, les maladies pulmonaires, les accidents vasculaires cérébraux, les maladies neurologiques, le diabète et les maladies rénales. De plus, 4 adultes sur 10 dans le pays souffrent de deux maladies chroniques ou plus. De plus, selon le communiqué de presse de l'European Chronic Disease Alliance (ECDA), en 2014, 9 personnes sur 10 en Europe meurent des suites de maladies chroniques. Ainsi, 70 à 80 % des coûts totaux des soins de santé sont consacrés à la gestion des maladies chroniques.



La prévalence croissante des maladies infectieuses, en particulier en Asie du Sud-Est, est également susceptible de propulser la demande d'API dans les années à venir, entraînant à terme la croissance du marché des intermédiaires pharmaceutiques. Par exemple, selon le rapport révisé sur le programme national de lutte contre la tuberculose, environ 4,4 lakh de patients sont décédés des suites de la tuberculose en Inde en 2018, soit 29 % du total de 1,5 million de décès causés par la maladie dans le monde. Ainsi, une prévalence aussi élevée de maladies chroniques et de maladies infectieuses renforce la demande de médicaments, mettant finalement en évidence le besoin d'intermédiaires pharmaceutiques.



Type-Based Insights



Le marché des intermédiaires pharmaceutiques, par type, est segmenté en GMP et non GMP. Le segment GMP détenait la plus grande part du marché en 2020, alors que le même segment devrait enregistrer le TCAC le plus élevé de 4,4 % sur le marché au cours de la période de prévision.




Marché des intermédiaires pharmaceutiques, par type - 2020 et 2028



Application-Based Insights



Le marché des intermédiaires pharmaceutiques, par application, est segmenté en antibiotiques, analgésiques antipyrétiques, vitamines et autres. Le segment des antibiotiques détenait la plus grande part du marché en 2020, également, ce segment devrait enregistrer le TCAC le plus élevé de 4,9 % sur le marché au cours de la période de prévision.




Aperçus basés sur le canal de distribution



Sur la base du canal de distribution, le marché des intermédiaires pharmaceutiques a été segmenté en distributeurs et ventes directes. Le segment des ventes directes détenait la plus grande part du marché en 2020, et le segment des distributeurs devrait enregistrer le TCAC le plus élevé de 4,2 % sur le marché au cours de la période de prévision.



Perspectives stratégiques



Les entreprises opérant sur le marché des intermédiaires pharmaceutiques adoptent des stratégies organiques telles que les lancements et les extensions de produits pour étendre leur empreinte et leur portefeuille de produits dans le monde entier ainsi que pour répondre aux demandes croissantes.



Par type



  • GMP

  • Non-GMP



Par application




  • Antibiotiques

  • Analgésiques antipyrétiques
  • Vitamines

  • Autres



Par canal de distribution




  • Distributeur

  • Ventes directes


Par géographie




  • Amérique du Nord

    • États-Unis

    • Canada

    • Mexique

  • Europe

    • Allemagne

    • France

    • Italie

    • Royaume-Uni
    • Espagne

    • Suisse

    • Belgique

    • Grèce

    • Norvège

    • Portugal

    • Suède

    • République tchèque

    • Croatie

    • Irlande

    • Danemark

    • Pays-Bas

    • Russie

    • Reste de l'Europe


  • Asie-Pacifique (APAC)

    • Chine

    • Inde
    • Corée du Sud

    • Japon

    • Australie

    • Reste de l'APAC


  • Moyen-Orient et Afrique (MEA )

    • Afrique du Sud

    • Arabie saoudite

    • EAU

    • Turquie

    • Reste de la MEA

    • Amérique du Sud et centrale (SCAM)

      • Brésil

      • Argentine

      • Reste de la SCAM

      < /li>


    Profils d'entreprise




    • Pfizer, Inc

    • Groupe Dishman

    • Dextra Laboratories Limited
    • Sanofi Winthrop Industries SA

    • Vertellus Holdings LLC

    • BASF SE

    • Lianhetech

    • Codexis

    • Midas Pharma GmbH

    • Chiracon GmbH

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are the driving factors for the Pharmaceutical Intermediates market across the globe?

Key factors that are driving the market are to rising prevalence of chronic diseases and infectious diseases, and escalating investment by pharmaceutical companies in R&D activities. However, high cost of drug manufacturing hinders the market growth.

What are Pharmaceutical Intermediates?

Pharmaceutical intermediates are the raw materials used to manufacture active pharmaceutical ingredients for the final drug formulation. Pharmaceutical intermediates are used in the production of bulk drugs as well as for research and development purpose by various pharm and biopharma companies. Pharmaceutical intermediates are formed at the time of process of production or synthesis of active pharmaceutical ingredients.

What is the cost of Pharmaceutical Intermediates?

The costs of the Pharmaceutical Intermediates are much higher, and they may cost US$ 5–50, or more, per kgs. The cost may also differ from product to product types.

The List of Companies - Pharmaceutical Intermediate Market

  1. Pfizer Inc.
  2. Sanofi
  3. BASF SE
  4. Lianhe Chemical Technology Co., Ltd
  5. Dishman Carbogen Amcis Ltd
  6. Codexis
  7. Midas Pharma GmbH
  8. chiracon GmbH
  9. Dextra Laboratories Limited
  10. Vertellus Holdings LLC

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports